Pub Date : 2013-05-01DOI: 10.14312/2052-4994.2013-19
Katz J, Bhattacharyya I, Moreb Js
Background: Paraneoplastic pemphigus (PNP) is an autoimmune mucocutaneous disease associated with cancer. Since the original description of the condition, various publications have suggested the presence of a heterogeneous spectrum of paraneoplastic mucocutaneous conditions with clinical features of lichenplanus. Several cases of PNP have been reported following treatment with fludarabine. Methods: We present a case of lichenoid syndrome in a follicular B-cell non-Hodgkin lymphoma (NHL) patient after treatment with fludarabine and review 8 additional published cases of fludarabine related PNP. Results: Our case is unique due to the fact that the patient presented with lichenoid features both clinically and microscopically and responded well to rituximab therapy. According to literature, both skin and mucosa (eyes and gastrointestinal tract) are involved and symptoms start about 1-2 weeks after exposure to fludarabine. Various immunosuppressive treatments have been employed including high dose steroids. Many of these patients developed complications related to the immunosuppressive therapy such as cytomegalovirus, candidiasis and pneumocystis carinii infection and died from respiratory failure. On the other hand, long-term remissions have also been described. Conclusion: Our case represents an unusual case of fludarabine related to mucocutaneous lichenoid syndrome, a variant of PNP, and in view of the outcome in previously described cases, rituximab may be considered a preferred and safe first line therapy for such complication.
{"title":"Lichenoid mucocutaneous syndrome a variant of para neoplastic pemphigus (PNP) following the treatment of follicular non-Hodgkin’s lymphoma with fludarabine","authors":"Katz J, Bhattacharyya I, Moreb Js","doi":"10.14312/2052-4994.2013-19","DOIUrl":"https://doi.org/10.14312/2052-4994.2013-19","url":null,"abstract":"Background: Paraneoplastic pemphigus (PNP) is an autoimmune mucocutaneous disease associated with cancer. Since the original description of the condition, various publications have suggested the presence of a heterogeneous spectrum of paraneoplastic mucocutaneous conditions with clinical features of lichenplanus. Several cases of PNP have been reported following treatment with fludarabine. Methods: We present a case of lichenoid syndrome in a follicular B-cell non-Hodgkin lymphoma (NHL) patient after treatment with fludarabine and review 8 additional published cases of fludarabine related PNP. Results: Our case is unique due to the fact that the patient presented with lichenoid features both clinically and microscopically and responded well to rituximab therapy. According to literature, both skin and mucosa (eyes and gastrointestinal tract) are involved and symptoms start about 1-2 weeks after exposure to fludarabine. Various immunosuppressive treatments have been employed including high dose steroids. Many of these patients developed complications related to the immunosuppressive therapy such as cytomegalovirus, candidiasis and pneumocystis carinii infection and died from respiratory failure. On the other hand, long-term remissions have also been described. Conclusion: Our case represents an unusual case of fludarabine related to mucocutaneous lichenoid syndrome, a variant of PNP, and in view of the outcome in previously described cases, rituximab may be considered a preferred and safe first line therapy for such complication.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"56 1","pages":"123-127"},"PeriodicalIF":0.0,"publicationDate":"2013-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73427530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-05-01DOI: 10.14312/2052-4994.2013-18
Leanza, L. Coco, G. Leanza, B. Scilletta, G. Zanchi, R. Vecchio, G. Zarbo
We present a case report of a 47-year-old woman who was admitted to our University-Hospital following diagnosis of pelvic mass. Abdominal examination revealed a tender, palpable mass on the right iliac region. At the gynecological examination uterus was regular in size. On the left side of the uterus a mass of 9 cm was observed; its surface was irregular and no mobility was found. Abdominal CT and NMR revealed massive ascites, omental cake and increased volume of both ovaries. Patient underwent longitudinal suprombelical-pubic laparotomy. After opening abdominal cavity, a free-fluid sample was taken and the results were positive for malignant cells. Typical neoplastic localizations on both ovaries, Douglas’ peritoneum, rectum, sigmoid colon and omentum were observed. Extemporaneous histological examination diagnosed a peritoneal serous papillary carcinoma. Hysterectomy with salpingo oophorectomy, total omentectomy, appendectomy, pelvic and lumbo-aortic lymphadenectomy was performed. Retroperitoneal approach to remove the whole Douglas’ peritoneum together with the pouch malignant localizations was done. Sigmoid colon and rectum were resected. A latero-terminal anastomosis with stapler was performed. All the visible abdominal maligant lesions were cut out. No transfusion was necessary. The postoperative course was regular and after seven days the patient was discharged. Chemotherapy ended the therapeutic management (six cycles of carboplatin with paclitaxel)|. After one year the patient is in good health and instrumental investigations (Ultrasounds, TC and NMR) are negative for recurrence. Such a case is very interesting for the discrepancy between slight symptoms and severity of the disease, the solution of which was very complex requiring a skillful polyspecialized oncological team.
{"title":"Primary peritoneal serous papillary carcinoma (PSPC) involving ovary and colon: Management and Treatment","authors":"Leanza, L. Coco, G. Leanza, B. Scilletta, G. Zanchi, R. Vecchio, G. Zarbo","doi":"10.14312/2052-4994.2013-18","DOIUrl":"https://doi.org/10.14312/2052-4994.2013-18","url":null,"abstract":"We present a case report of a 47-year-old woman who was admitted to our University-Hospital following diagnosis of pelvic mass. Abdominal examination revealed a tender, palpable mass on the right iliac region. At the gynecological examination uterus was regular in size. On the left side of the uterus a mass of 9 cm was observed; its surface was irregular and no mobility was found. Abdominal CT and NMR revealed massive ascites, omental cake and increased volume of both ovaries. Patient underwent longitudinal suprombelical-pubic laparotomy. After opening abdominal cavity, a free-fluid sample was taken and the results were positive for malignant cells. Typical neoplastic localizations on both ovaries, Douglas’ peritoneum, rectum, sigmoid colon and omentum were observed. Extemporaneous histological examination diagnosed a peritoneal serous papillary carcinoma. Hysterectomy with salpingo oophorectomy, total omentectomy, appendectomy, pelvic and lumbo-aortic lymphadenectomy was performed. Retroperitoneal approach to remove the whole Douglas’ peritoneum together with the pouch malignant localizations was done. Sigmoid colon and rectum were resected. A latero-terminal anastomosis with stapler was performed. All the visible abdominal maligant lesions were cut out. No transfusion was necessary. The postoperative course was regular and after seven days the patient was discharged. Chemotherapy ended the therapeutic management (six cycles of carboplatin with paclitaxel)|. After one year the patient is in good health and instrumental investigations (Ultrasounds, TC and NMR) are negative for recurrence. Such a case is very interesting for the discrepancy between slight symptoms and severity of the disease, the solution of which was very complex requiring a skillful polyspecialized oncological team.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"89 1","pages":"119-122"},"PeriodicalIF":0.0,"publicationDate":"2013-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87031423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-04-01DOI: 10.14312/2052-4994.2013-10
Agaku It, Adisa Ao
Background: Surgery is commonly favored in the management of oral cancer but radiotherapy may be essential because of the size or location of the tumor. Refusal of radiotherapy by patients is an important issue, which must be taken into consideration during treatment planning. This study assessed prevalence and correlates of radiotherapy refusal among oral cancer patients. Methods: Data was analyzed for 47, 174 oral cancer cases in the Surveillance, Epidemiology and End Results (SEER) database during 1988–2008. Point estimates were calculated overall and by selected socio-demographic and clinical characteristics. A multivariate logistic regression model was fitted to determine predictors of radiotherapy refusal. Results: The overall prevalence of refusal of radiotherapy was 2.31%. Factors associated with increased likelihood of refusal of radiotherapy included age 45 years (adjusted odds ratio, aOR2.48; P0.031); gingival/floor of mouth tumors (aOR1.32; P0.010); receipt of surgery (aOR1.21; P0.04). Conversely, protective factors included being married (aOR0.59; P0.001); non-Hispanic blacks (aOR0.53; P0.001); involvement of paired structures (aOR0.61; P0.001) as well as multiple tumors (aOR0.75; P0.021). Sex was not a significant predictor on multivariate analysis. Conclusion: Prevalence of refusal of radiotherapy among oral cancer patients is relatively low and is significantly associated with age, marital status, as well as location, extent and severity of disease. Clinicians may anticipate patients likely to refuse radiotherapy and develop patient-tailored counseling considering the benefits and risks of proposed treatment. Final treatment decision must however take into consideration the wishes of the fully informed patient.
{"title":"Factors associated with refusal of radiotherapy among oral cancer patients","authors":"Agaku It, Adisa Ao","doi":"10.14312/2052-4994.2013-10","DOIUrl":"https://doi.org/10.14312/2052-4994.2013-10","url":null,"abstract":"Background: Surgery is commonly favored in the management of oral cancer but radiotherapy may be essential because of the size or location of the tumor. Refusal of radiotherapy by patients is an important issue, which must be taken into consideration during treatment planning. This study assessed prevalence and correlates of radiotherapy refusal among oral cancer patients. Methods: Data was analyzed for 47, 174 oral cancer cases in the Surveillance, Epidemiology and End Results (SEER) database during 1988–2008. Point estimates were calculated overall and by selected socio-demographic and clinical characteristics. A multivariate logistic regression model was fitted to determine predictors of radiotherapy refusal. Results: The overall prevalence of refusal of radiotherapy was 2.31%. Factors associated with increased likelihood of refusal of radiotherapy included age 45 years (adjusted odds ratio, aOR2.48; P0.031); gingival/floor of mouth tumors (aOR1.32; P0.010); receipt of surgery (aOR1.21; P0.04). Conversely, protective factors included being married (aOR0.59; P0.001); non-Hispanic blacks (aOR0.53; P0.001); involvement of paired structures (aOR0.61; P0.001) as well as multiple tumors (aOR0.75; P0.021). Sex was not a significant predictor on multivariate analysis. Conclusion: Prevalence of refusal of radiotherapy among oral cancer patients is relatively low and is significantly associated with age, marital status, as well as location, extent and severity of disease. Clinicians may anticipate patients likely to refuse radiotherapy and develop patient-tailored counseling considering the benefits and risks of proposed treatment. Final treatment decision must however take into consideration the wishes of the fully informed patient.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"14 1","pages":"62-69"},"PeriodicalIF":0.0,"publicationDate":"2013-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73210044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-04-01DOI: 10.14312/2052-4994.2013-13
I. Goshev, A. Mavrova, B. Mihaylova, D. Wesselinova
A group of bis(benzimidazol-2-yl) amines have been already evaluated for cytotoxicity in vitro to human colorectal cancer cell line HT-29, breast cancer cells MDA-MB-231 and normal spleen cells and two of them (B1 and B2) have been taken for the purposes of our present investigations. From the second group of compounds representing 1,3-disubstituted-2,3-dihydro-2-iminobenzimidazoles two substances (B3 and B4) have been chosen because of their most pronounced anti-proliferative effect to human colorectal cancer cell line HT-29, breast cancer cells MDA-MB-231 and normal spleen cells, using the in vitro proliferative MTS-test. It was important to estimate the cause for this suppressive activity of the compounds. We proposed that this could be due to their antioxidant capacity. The substances were examined for antioxidant activity against hydroxyl and peroxyl radicals, applying the HORAC and ORAC methods and showed considerable capacity. The scavenging capacity of B2 towards hydroxyl radicals is the highest, followed by B1. It was estimated that B2 has the greatest scavenger capacity of oxygen radicals, emitted by the examined cells followed in descending order by B1, B3 and B4. The observed differences can be considered as impact of their structure on the Me2-helating activity and effective H-atom donation. A correlation was observed between the structure of the particular substance and the expressed antioxidant potential. The latter correlated also with the effect on the tested tumor cell lines. This result means that tumor cells are accompanied by a measurable emission of ROS which might be regulated by a proper application of antioxidants.
{"title":"Antioxidant activity of some benzimidazole derivatives to definite tumor cell lines","authors":"I. Goshev, A. Mavrova, B. Mihaylova, D. Wesselinova","doi":"10.14312/2052-4994.2013-13","DOIUrl":"https://doi.org/10.14312/2052-4994.2013-13","url":null,"abstract":"A group of bis(benzimidazol-2-yl) amines have been already evaluated for cytotoxicity in vitro to human colorectal cancer cell line HT-29, breast cancer cells MDA-MB-231 and normal spleen cells and two of them (B1 and B2) have been taken for the purposes of our present investigations. From the second group of compounds representing 1,3-disubstituted-2,3-dihydro-2-iminobenzimidazoles two substances (B3 and B4) have been chosen because of their most pronounced anti-proliferative effect to human colorectal cancer cell line HT-29, breast cancer cells MDA-MB-231 and normal spleen cells, using the in vitro proliferative MTS-test. It was important to estimate the cause for this suppressive activity of the compounds. We proposed that this could be due to their antioxidant capacity. The substances were examined for antioxidant activity against hydroxyl and peroxyl radicals, applying the HORAC and ORAC methods and showed considerable capacity. The scavenging capacity of B2 towards hydroxyl radicals is the highest, followed by B1. It was estimated that B2 has the greatest scavenger capacity of oxygen radicals, emitted by the examined cells followed in descending order by B1, B3 and B4. The observed differences can be considered as impact of their structure on the Me2-helating activity and effective H-atom donation. A correlation was observed between the structure of the particular substance and the expressed antioxidant potential. The latter correlated also with the effect on the tested tumor cell lines. This result means that tumor cells are accompanied by a measurable emission of ROS which might be regulated by a proper application of antioxidants.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"19 1","pages":"87-91"},"PeriodicalIF":0.0,"publicationDate":"2013-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81834228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-04-01DOI: 10.14312/2052-4994.2013-12
R. Al, E. Destefani, H. Deneo‐Pellegrini
{"title":"Body composition, somatotype and risk of premenopausal breast cancer: a case-control study in Uruguay","authors":"R. Al, E. Destefani, H. Deneo‐Pellegrini","doi":"10.14312/2052-4994.2013-12","DOIUrl":"https://doi.org/10.14312/2052-4994.2013-12","url":null,"abstract":"","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"31 1","pages":"77-86"},"PeriodicalIF":0.0,"publicationDate":"2013-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82620948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-04-01DOI: 10.14312/2052-4994.2013-14
C. Hugo, G. Hurtevent, S. Ferron, M. Boisserie-Lacroix, M. Longy, A. Floquet, Brouste, M. Asad-Syed
Objectives: To examine intra-observer reliability (IR) for lesion detection on contrast-enhanced breast magnetic resonance images (MRI) for screening women at high risk of breast cancer in single and joint double readings, without case selection. Methods: Contrastenhanced breast MRIs were interpreted twice by the same independent reader and twice in joint readings. IR was assessed for lesion detection, normal MRI identification, mass, non-mass like enhancements (NMLE) and focus characterisation, and BI-RADS assessment. Results: MRI examinations for 124 breasts, 65 women (mean age 43.4y) were retrospectively reviewed with 110 lesions identified. Abnormal BI-RADS (3-5) classifications were found for 52.3% in single readings and 58.5% in joint readings. Seven biopsies were performed for 4 histologically confirmed cancers. IR for BI-RADS classifications was good for single (0.63, 95% CI: 0.49-0.77), and joint readings (0.77, 95% CI: 0.61-0.93). IR for background parenchymal enhancement (BPE) was moderate across single (0.53, 95% CI: 0.40-0.65) and joint readings (0.44, 95% CI: 0.33-0.56). IR for BI-RADS category according to each enhancement was poor for single (0.27, 95% CI: 0.10-0.44), and higher for joint readings, (0.58, 95% CI: 0.43-0.72). Conclusions: IR in BI-RADS breast assessments or BI-RADS lesion assessments are better with joint reading in screening for women with high genetic risks, in particular for abnormal MRI (BI-RADS 3, 4 and 5).
{"title":"Intra-observer agreement in single and joint double readings of contrast-enhanced breast MRI screening for women with high genetic breast cancer risks","authors":"C. Hugo, G. Hurtevent, S. Ferron, M. Boisserie-Lacroix, M. Longy, A. Floquet, Brouste, M. Asad-Syed","doi":"10.14312/2052-4994.2013-14","DOIUrl":"https://doi.org/10.14312/2052-4994.2013-14","url":null,"abstract":"Objectives: To examine intra-observer reliability (IR) for lesion detection on contrast-enhanced breast magnetic resonance images (MRI) for screening women at high risk of breast cancer in single and joint double readings, without case selection. Methods: Contrastenhanced breast MRIs were interpreted twice by the same independent reader and twice in joint readings. IR was assessed for lesion detection, normal MRI identification, mass, non-mass like enhancements (NMLE) and focus characterisation, and BI-RADS assessment. Results: MRI examinations for 124 breasts, 65 women (mean age 43.4y) were retrospectively reviewed with 110 lesions identified. Abnormal BI-RADS (3-5) classifications were found for 52.3% in single readings and 58.5% in joint readings. Seven biopsies were performed for 4 histologically confirmed cancers. IR for BI-RADS classifications was good for single (0.63, 95% CI: 0.49-0.77), and joint readings (0.77, 95% CI: 0.61-0.93). IR for background parenchymal enhancement (BPE) was moderate across single (0.53, 95% CI: 0.40-0.65) and joint readings (0.44, 95% CI: 0.33-0.56). IR for BI-RADS category according to each enhancement was poor for single (0.27, 95% CI: 0.10-0.44), and higher for joint readings, (0.58, 95% CI: 0.43-0.72). Conclusions: IR in BI-RADS breast assessments or BI-RADS lesion assessments are better with joint reading in screening for women with high genetic risks, in particular for abnormal MRI (BI-RADS 3, 4 and 5).","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"61 1","pages":"92-98"},"PeriodicalIF":0.0,"publicationDate":"2013-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89794711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-04-01DOI: 10.14312/2052-4994.2013-15
R. Conca, G. Roviello, A. Cerase, M. Mazzei, C. Miracco, Mastrogiulio Mg, S. Marsili, G. Francini
Meningiomas are common intracranial tumors which usually pursue a benign course. Extracranial metastases from meningiomas are very rare and the lung is the most common site. We report a 27 year old girl with an intracranial atypical meningioma with pulmonary metastasis which had been misdiagnosed as lung sequestration upon chest CT examination. She underwent subtotal surgical resection of the meningioma in 2006 and surgical removal of the lung metastasis in 2009. Then, the patient developed pleural, lung, periesophageal and diaphragmatic nodal metastases, despite only subtle increase of the intracranial residual meningioma. Therefore, she was treated by Doxil (pegylated liposomal doxorubicin) and bevacizumab with a progression of disease after three cycles and then with hydroxyurea for two months with a dimensional increase of metastatic lesions. After adding sorafenib to hydroxyurea the patient showed a further progression disease and finally died for respiratory insufficiency. Metastatic meningiomas have been rarely reported. Hydroxyurea is one of the most used drug in recurrent and metastatic meningiomas, despite modest results are obtained. Further chemotherapy strategies or biological agent must be investigated in clinical trials.
{"title":"Treatment of an atypical metastatic meningioma: a case report","authors":"R. Conca, G. Roviello, A. Cerase, M. Mazzei, C. Miracco, Mastrogiulio Mg, S. Marsili, G. Francini","doi":"10.14312/2052-4994.2013-15","DOIUrl":"https://doi.org/10.14312/2052-4994.2013-15","url":null,"abstract":"Meningiomas are common intracranial tumors which usually pursue a benign course. Extracranial metastases from meningiomas are very rare and the lung is the most common site. We report a 27 year old girl with an intracranial atypical meningioma with pulmonary metastasis which had been misdiagnosed as lung sequestration upon chest CT examination. She underwent subtotal surgical resection of the meningioma in 2006 and surgical removal of the lung metastasis in 2009. Then, the patient developed pleural, lung, periesophageal and diaphragmatic nodal metastases, despite only subtle increase of the intracranial residual meningioma. Therefore, she was treated by Doxil (pegylated liposomal doxorubicin) and bevacizumab with a progression of disease after three cycles and then with hydroxyurea for two months with a dimensional increase of metastatic lesions. After adding sorafenib to hydroxyurea the patient showed a further progression disease and finally died for respiratory insufficiency. Metastatic meningiomas have been rarely reported. Hydroxyurea is one of the most used drug in recurrent and metastatic meningiomas, despite modest results are obtained. Further chemotherapy strategies or biological agent must be investigated in clinical trials.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"365 1","pages":"99-104"},"PeriodicalIF":0.0,"publicationDate":"2013-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85211910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-04-01DOI: 10.14312/2052-4994.2013-16
J. Keogh, Christian U. Krägeloh, D. Shepherd, Clare Ryan, S. Osborne, J. Masters, Roderick D. MacLeod
Men with prostate cancer experience many challenges to their quality of life (QOL). While some of these challenges reflect the direct effects of the cancer, additional side-effects and symptoms are also associated with common treatments especially androgen deprivation therapy (ADT). While several studies have examined the effects of ADT on the QOL of men with prostate cancer, much of this research is between 10-20 years old and was conducted in North America or Europe. This study therefore examined the effects of ADT on QOL in prostate cancer patients (survivors) in the Southern hemisphere. The registries of two New Zealand based hospitals were sourced to identify men with prostate cancer who were using ADT for at least six months (ADT group, n=205) and those who had never used ADT (non-ADT group, n=143). Participants in both groups were mailed a letter of invitation, the WHOQOL-BREF and three facets of the WHOQOL-OLD QOL questionnaire. Response rates of 41% and 40% were obtained for the ADT and non-ADT groups, respectively. QOL scores were generally similar between the groups, with the exception of physical QOL, which was significantly lower in the ADT group. Such results suggest that cancer clinicians, allied health professionals and cancer researchers should not just concentrate on the physical effect of ADT on their survivors’ risk of developing osteoporosis, falls-related fracture and cardio-metabolic syndrome, but also devote time to ensure their survivors’ perception of their physical QOL is not compromised.
{"title":"Quantitative assessment of quality of life in New Zealand prostate cancer survivors: the effect of androgen deprivation therapy","authors":"J. Keogh, Christian U. Krägeloh, D. Shepherd, Clare Ryan, S. Osborne, J. Masters, Roderick D. MacLeod","doi":"10.14312/2052-4994.2013-16","DOIUrl":"https://doi.org/10.14312/2052-4994.2013-16","url":null,"abstract":"Men with prostate cancer experience many challenges to their quality of life (QOL). While some of these challenges reflect the direct effects of the cancer, additional side-effects and symptoms are also associated with common treatments especially androgen deprivation therapy (ADT). While several studies have examined the effects of ADT on the QOL of men with prostate cancer, much of this research is between 10-20 years old and was conducted in North America or Europe. This study therefore examined the effects of ADT on QOL in prostate cancer patients (survivors) in the Southern hemisphere. The registries of two New Zealand based hospitals were sourced to identify men with prostate cancer who were using ADT for at least six months (ADT group, n=205) and those who had never used ADT (non-ADT group, n=143). Participants in both groups were mailed a letter of invitation, the WHOQOL-BREF and three facets of the WHOQOL-OLD QOL questionnaire. Response rates of 41% and 40% were obtained for the ADT and non-ADT groups, respectively. QOL scores were generally similar between the groups, with the exception of physical QOL, which was significantly lower in the ADT group. Such results suggest that cancer clinicians, allied health professionals and cancer researchers should not just concentrate on the physical effect of ADT on their survivors’ risk of developing osteoporosis, falls-related fracture and cardio-metabolic syndrome, but also devote time to ensure their survivors’ perception of their physical QOL is not compromised.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"13 2 1","pages":"105-110"},"PeriodicalIF":0.0,"publicationDate":"2013-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79639715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-04-01DOI: 10.14312/2052-4994.2013-11
C. Akladios, G. Bour, Z. Raykov, D. Mutter, J. Marescaux, M. Aprahamian
The aim of the study was to evaluate the feasibility of a longitudinal non-invasive monitoring of rat pancreatic ductal adenocarcinoma (PDAC) using microCTscans (CT). The identification of the pancreatic gland on (CT) was performed at first using contrast products (Fenestra LC and VC, v/v) at a dosage of 0.5 ml/Kg of body weight. Then orthotopic PDAC developed in adult Lewis rat was detected and monitored. In vivo CT measurement of tumor was compared to actual size ex vivo in 12 rats. Gemcitabine treatment of PDAC was monitored at two week intervals until defined endpoints (liver metastasis or ascitis) in 10 rats versus 10 controls. CT had a 100% positive predictive value in the detection of orthotropic PDAC. Regression analysis showed a linear correlation between ex vivo and in vivo CT tumor measurements. Longitudinal evaluation of tumor progression showed a reduction in tumor growth (P<0.05 at 8 weeks) and a slightly prolonged survival (P=0.15) under gemcitabine treatment. In conclusion CT appears to be a cost-effective mean for preclinical study of PDAC saving time, animals, while respecting animal welfare. It could be considered as an efficient tool in anticancer drug research and development.
{"title":"Structural imaging of the pancreas in rat using micro-CT: application to a non-invasive longitudinal evaluation of pancreatic ductal carcinoma monitoring","authors":"C. Akladios, G. Bour, Z. Raykov, D. Mutter, J. Marescaux, M. Aprahamian","doi":"10.14312/2052-4994.2013-11","DOIUrl":"https://doi.org/10.14312/2052-4994.2013-11","url":null,"abstract":"The aim of the study was to evaluate the feasibility of a longitudinal non-invasive monitoring of rat pancreatic ductal adenocarcinoma (PDAC) using microCTscans (CT). The identification of the pancreatic gland on (CT) was performed at first using contrast products (Fenestra LC and VC, v/v) at a dosage of 0.5 ml/Kg of body weight. Then orthotopic PDAC developed in adult Lewis rat was detected and monitored. In vivo CT measurement of tumor was compared to actual size ex vivo in 12 rats. Gemcitabine treatment of PDAC was monitored at two week intervals until defined endpoints (liver metastasis or ascitis) in 10 rats versus 10 controls. CT had a 100% positive predictive value in the detection of orthotropic PDAC. Regression analysis showed a linear correlation between ex vivo and in vivo CT tumor measurements. Longitudinal evaluation of tumor progression showed a reduction in tumor growth (P<0.05 at 8 weeks) and a slightly prolonged survival (P=0.15) under gemcitabine treatment. In conclusion CT appears to be a cost-effective mean for preclinical study of PDAC saving time, animals, while respecting animal welfare. It could be considered as an efficient tool in anticancer drug research and development.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"8 1","pages":"70-76"},"PeriodicalIF":0.0,"publicationDate":"2013-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79328331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-03-01DOI: 10.14312/2052-4994.2013-8
L. Ansaloni, M. Lotti, L. Campanati, P. Bertoli, E. Poiasina, M. Mandalà, F. Coccolini
Gastric cancer is the fourth most common cancer and the second leading cause of cancer death in the world. Penetration of the gastric serosa and lymphatic spread are the two most important factors affecting prognosis in gastric cancer. Patients with peritoneal carcinomatosis from gastric cancer show a particularly poor prognosis. A few treatment strategies have been tested and proposed to increase survival rates. The cornerstone of treatment remains complete cytoreductive surgery associated with a different combination of chemotherapy regimen. It has been demonstrated as systemic adjuvant, systemic neoadjuvant and above all hyperthermic intraperitoneal chemotherapy improve the survival, when used in the prevention and treatment of peritoneal carcinomatosis from gastric cancer. Few new molecules have been introduced enhancing the effect of chemotherapy by biologically targeting its objective. However further studies are needed.
{"title":"The prevention and treatment of peritoneal carcinomatosis from gastric cancer: A 2013 update","authors":"L. Ansaloni, M. Lotti, L. Campanati, P. Bertoli, E. Poiasina, M. Mandalà, F. Coccolini","doi":"10.14312/2052-4994.2013-8","DOIUrl":"https://doi.org/10.14312/2052-4994.2013-8","url":null,"abstract":"Gastric cancer is the fourth most common cancer and the second leading cause of cancer death in the world. Penetration of the gastric serosa and lymphatic spread are the two most important factors affecting prognosis in gastric cancer. Patients with peritoneal carcinomatosis from gastric cancer show a particularly poor prognosis. A few treatment strategies have been tested and proposed to increase survival rates. The cornerstone of treatment remains complete cytoreductive surgery associated with a different combination of chemotherapy regimen. It has been demonstrated as systemic adjuvant, systemic neoadjuvant and above all hyperthermic intraperitoneal chemotherapy improve the survival, when used in the prevention and treatment of peritoneal carcinomatosis from gastric cancer. Few new molecules have been introduced enhancing the effect of chemotherapy by biologically targeting its objective. However further studies are needed.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"68 1","pages":"54-59"},"PeriodicalIF":0.0,"publicationDate":"2013-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87252907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：